Health.Global

Why is Healthcare Global Enterprises Ltd falling/rising?

As of 10-Jun, Healthcare Global Enterprises Ltd's stock price is rising to 635.65, with a 1.8 (0.28%) increase, and has outperformed its sector. The stock has gained 16.90% over the past year, significantly exceeding the Sensex's decline, supported by strong financial metrics and healthy growth prospects.

As of 10-Jun, Healthcare Global Enterprises Ltd's stock price is rising, currently at 635.65, with a change of 1.8 (0.28%) upward. The stock has shown a positive performance today, outperforming its sector by 1.33%. It has been gaining for the last two days, with a total increase of 1.55% during this period. <BR><BR>In terms of longer-term performance, the stock has generated a return of 16.90% over the past year, significantly outperforming the benchmark Sensex, which has declined by 10.21% in the same timeframe. Additionally, the stock has demonstrated strong growth metrics, with an operating profit growth of 19.15% and a remarkable increase in profit after tax (PAT) of 363.0% in the most recent quarter.<BR><BR>Despite a recent decline in investor participation, as indicated by an 80.29% drop in delivery volume compared to the 5-day average, the stock remains liquid enough for trading. The company's healthy long-term growth prospects, supported by a low debt-equity ratio of 1.30 times and high institutional holdings at 21.61%, further contribute to its rising stock price. Overall, the combination of solid financial results, market-beating performance, and attractive valuations compared to peers supports the upward movement of Healthcare Global Enterprises Ltd's stock.

What does Health.Global do?

HealthCare Global Enterprises Ltd operates in the hospital industry, focusing on oncology services. As of March 2026, it reported net sales of 652 Cr and a net profit of 2 Cr, with a market cap of INR 9,545 Cr.

Overview: <BR>Healthcare Global Enterprises Ltd operates in the hospital industry and is classified as a small-cap company.<BR><BR>History: <BR>The company was originally incorporated as Curie Centre of Oncology Private Limited in 1998. It underwent a name change to HealthCare Global Enterprises Private Limited in 2005 and was converted into a Public Limited Company in 2006, adopting its current name. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 652 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 9,545 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 164.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.90 <BR>Return on Equity: 4.38% <BR>Price to Book: 7.13 <BR><BR>Contact Details: <BR>Address: HCG Tower No 8 Kalinga Rao Rd, Sampangi Rama Nagar Bangalore Karnataka : 560027 <BR>Tel: 91-80-4660-7700 <BR>Email: sunumanuel@hcgoncology.com <BR>Website: http://www.hcgel.com

Which are the latest news on Health.Global?

Are Healthcare Global Enterprises Ltd latest results good or bad?

Healthcare Global Enterprises Ltd's latest results are concerning, showing a 70.52% decline in net profit despite an 11.48% increase in net sales. The company's financial challenges, including high interest costs and low return on equity, overshadow its revenue growth.

Healthcare Global Enterprises Ltd's latest results present a mixed picture, leaning towards the negative side. In the fourth quarter of FY26, the company reported consolidated net profit of ₹2.17 crores, which is a significant decline of 70.52% year-on-year. This sharp drop in profitability raises concerns about the company's ability to convert its revenue growth into actual earnings.<BR><BR>On the positive side, net sales reached ₹652.33 crores, reflecting an 11.48% increase year-on-year, which indicates strong revenue generation capabilities. Additionally, the operating margin improved to 19.23%, suggesting better operational efficiency.<BR><BR>However, the stark contrast between rising revenues and plummeting profits highlights serious underlying issues. High interest costs and depreciation, along with a very low return on equity of 3.84%, indicate that the company is struggling to manage its capital effectively. Furthermore, the stock has underperformed compared to its peers in the hospital sector, which raises further concerns about its market position and valuation.<BR><BR>Overall, while there are some positive aspects in terms of revenue growth and operational margins, the significant decline in net profit and the company's financial challenges suggest that the latest results are more concerning than encouraging.

Should I buy, sell or hold Healthcare Global Enterprises Ltd?

Is Health.Global technically bullish or bearish?

As of December 3, 2025, the trend is mildly bullish due to positive daily moving averages and Bollinger Bands, but caution is advised due to mixed signals from the MACD, KST, and monthly RSI.

As of 3 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullishness and the Bollinger Bands showing a mildly bullish signal on both weekly and monthly time frames. However, the MACD and KST on the weekly are mildly bearish, and the monthly RSI is bearish, suggesting some caution. Overall, the mixed signals indicate a mildly bullish outlook with underlying weaknesses that could affect momentum.

Is Health.Global overvalued or undervalued?

As of November 24, 2025, Health.Global is considered undervalued with an attractive valuation grade, despite having a high PE ratio of 286.73 and an EV to EBITDA ratio of 27.53, while outperforming the Sensex with a 53.86% return over the past year.

As of 24 November 2025, Health.Global's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 286.73, an EV to EBITDA ratio of 27.53, and a ROCE of 7.64%. <BR><BR>In the peer comparison, Health.Global's PE ratio significantly exceeds that of Apollo Hospitals, which stands at 63.22, while its EV to EBITDA ratio is also higher than Apollo's 33.25. This suggests that Health.Global may be overvalued on a relative basis despite its attractive grade. Notably, the company's stock has outperformed the Sensex over the past year, returning 53.86% compared to the Sensex's 7.31%, reinforcing the notion of its strong market performance despite the high valuation ratios.

How has been the historical performance of Health.Global?

Health.Global has shown strong growth in net sales, reaching 2,222.85 Cr in March 2025, with operating profit increasing to 387.28 Cr and a margin of 17.46%. However, profit before tax declined to 56.19 Cr, and the company faces cash management challenges despite improved operating cash flow.

Answer:<BR>The historical performance of Health.Global shows a significant upward trend in net sales and operating profit over the past several years, culminating in a net sales figure of 2,222.85 Cr for the year ending March 2025, up from 1,912.12 Cr in March 2024 and 1,694.44 Cr in March 2023. The total operating income has also increased consistently, reaching 2,222.85 Cr in March 2025. Operating profit, excluding other income, rose to 387.28 Cr in March 2025 from 329.59 Cr in March 2024, reflecting a healthy operating profit margin of 17.46%. However, profit before tax decreased to 56.19 Cr in March 2025 from 67.33 Cr in March 2024, leading to a profit after tax of 48.06 Cr, slightly up from 40.93 Cr the previous year. <BR><BR>In terms of assets and liabilities, total assets increased to 3,518.24 Cr in March 2025 from 2,700.44 Cr in March 2024, while total liabilities also rose to 3,518.24 Cr, indicating a balanced growth. The company’s total debt increased to 1,002.23 Cr in March 2025 from 672.76 Cr in March 2024. Cash flow from operating activities improved to 317.00 Cr in March 2025, although the net cash outflow was recorded at -213.00 Cr, indicating challenges in cash management. Overall, Health.Global has shown growth in sales and operating profit, but faces pressures on profitability and cash flow management.<BR><BR>Breakdown:<BR>Health.Global has demonstrated a robust growth trajectory in net sales, which reached 2,222.85 Cr in March 2025, marking a significant increase from 1,912.12 Cr in March 2024 and 1,694.44 Cr in March 2023. The total operating income mirrored this growth, also hitting 2,222.85 Cr in March 2025. Operating profit, excluding other income, rose to 387.28 Cr, up from 329.59 Cr the previous year, resulting in an operating profit margin of 17.46%. Despite this positive trend, profit before tax saw a decline to 56.19 Cr in March 2025 from 67.33 Cr in March 2024, leading to a profit after tax of 48.06 Cr, which is an increase from 40.93 Cr in the prior year. <BR><BR>On the balance sheet, total assets surged to 3,518.24 Cr in March 2025, compared to 2,700.44 Cr in March 2024, while total liabilities matched this figure, indicating a balanced growth. The total debt increased to 1,002.23 Cr in March 2025 from 672.76 Cr in March 2024. Cash flow from operating activities improved to 317.00 Cr, yet the company faced a net cash outflow of -213.00 Cr, highlighting ongoing challenges in cash management despite the growth in sales and operating profit.

Who are the top shareholders of the Health.Global?

The top shareholders of Health.Global include Aceso Company Pte. Ltd. with 60.35%, followed by mutual funds at 9.19%, individual investors at 10.43%, and foreign institutional investors at 2.45%. The largest public shareholder is Tata India Pharma & Healthcare Fund, owning 3.42%.

The top shareholders of Health.Global include Aceso Company Pte. Ltd., which holds the largest stake at 60.35%. The promoters are the majority shareholders, with a pledged promoter holding of 4.995%. Additionally, mutual funds hold 9.19% of the shares across 9 schemes, while foreign institutional investors (FIIs) have a combined holding of 2.45% through 85 different entities. The highest public shareholder is Tata India Pharma & Healthcare Fund, which owns 3.42%. Individual investors collectively hold 10.43% of the company's shares.

how big is Health.Global?

As of October 2023, Healthcare Global Enterprises Ltd has a market capitalization of 7,641.00 Cr and reported net sales of 2,222.85 Cr and net profit of 44.41 Cr over the latest four quarters. Shareholder's funds are 825.78 Cr, with total assets of 2,700.44 Cr as of March 2024.

Market Cap: Healthcare Global Enterprises Ltd has a market capitalization of 7,641.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 2,222.85 Cr. The sum of Net Profit for the same period is 44.41 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds amount to 825.78 Cr, and the Total Assets are valued at 2,700.44 Cr.

Who are in the management team of Health.Global?

As of March 2023, the management team of Health.Global includes Chairman/CEO Basavalinga Ajai Kumar Sadashivaiah, Executive Director Anjali Ajaikumar Rossi, and several independent and non-executive directors, overseeing the company's strategic direction and governance.

As of March 2023, the management team of Health.Global includes the following individuals:<BR><BR>1. BASAVALINGA AJAIKUMAR SADASHIVAIAH - Chairman/ED & CEO<BR>2. Siddharth Patel - Non Executive Director / Nomin<BR>3. Anjali Ajaikumar Rossi - Executive Director<BR>4. Geet Mathur - Independent Non Executive Director<BR>5. RAJAGOPALAN RAGHAVAN - Independent Non Executive Director<BR>6. Pradip M. Kanakia - Independent Non Executive Director<BR>7. Meghraj Arvindrao Gore - Whole Time Director & CEO<BR>8. AMIT SONI - Non Executive Director / Nomin<BR>9. Rajiv Maliwal - Independent Non Executive Director<BR>10. SUNU MANUEL - Company Secretary & Compliance Officer<BR><BR>This team is responsible for the strategic direction and governance of the company.

When is the next results date for Health.Global?

No Upcoming Board Meetings

Has Health.Global declared dividend?

No Dividend History Available

Who are the peers of the Health.Global?

Health.Global's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Kovai Medical, Yatharth Hospital, Indraprastha Medical, and Artemis Medicare. Key metrics show varying management risks, growth rates, and capital structures, with Indraprastha Medical leading in 1-year returns at 78.47% and Global Health at the lowest with 4.29%.

Peers: The peers of Health.Global are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Kovai Medical, Yatharth Hospit., Indrapr.Medical, Artemis Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Kovai Medical, and Indrapr.Medical, while Average management risk is found at Fortis Health., Yatharth Hospit., and Artemis Medicare, and the rest have Below Average management risk. Excellent growth is seen at Max Healthcare and Apollo Hospitals, while Good growth is noted at Fortis Health., Narayana Hrudaya, Health.Global, Yatharth Hospit., and Indrapr.Medical, with Average growth at Global Health and Below Average growth at Kovai Medical and Artemis Medicare. Excellent capital structure is present at Max Healthcare, Global Health, and Indrapr.Medical, while Good capital structure is found at Fortis Health., Narayana Hrudaya, Kovai Medical, and Yatharth Hospit., and the rest have Average or Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indrapr.Medical at 78.47%, while the lowest is Global Health at 4.29%. Health.Global's 1-year return of 54.56% is higher than Global Health's but lower than Indrapr.Medical's. Additionally, peers with negative six-month returns include Yatharth Hospit. and Artemis Medicare.